A randomized, open-label phase 2 study of the TORC 1/2 inhibitor sapanisertib in relapsed/refractory (R/R) NFE2l2 (NRF2)-mutated and wild-type (WT) squamous non-small cell lung cancer (sqNSCLC) Meeting Abstract
| Authors: | Riess, J. W.; Johnson, M. L.; Gadgeel, S.; Skoulidis, F.; Sumrow, B.; Kuriakose, E.; Albert, K.; Kittrell, N.; Akella, L.; Fiji, G.; Paik, P. |
| Abstract Title: | A randomized, open-label phase 2 study of the TORC 1/2 inhibitor sapanisertib in relapsed/refractory (R/R) NFE2l2 (NRF2)-mutated and wild-type (WT) squamous non-small cell lung cancer (sqNSCLC) |
| Meeting Title: | 2022 North America Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 18 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2022 Sep 23-25 |
| Meeting Location: | Chicago, IL |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-03-01 |
| Start Page: | e14 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.09.036 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: PP01.10 -- Accession Number: 161552910 -- Entry Date: In Process -- Revision Date: 20230131 -- Publication Type: Article -- Supplement Title: Mar2023:Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
